American Association of Immunologists

Table I.

Multilineage analysis^a

n^b	% Donor	Percentage in Donor (H2K^d+) Lymphoid Gate^c
n^b	% Donor			αβ-TCR	CD8	CD4	B220	DX5	Mac-1	Gr-1	CD11c
A^d 11	99.7 ± 0.5	20.0 ± 5.5	2.5 ± 0.9	17.6 ± 5.7	73.7 ± 5.2	6.3 ± 5.0	2.2 ± 0.5	1.0 ± 0.3	1.1 ± 0.1
B^e 10	15.6 ± 8.9	13.9 ± 6.2	1.8 ± 1.1	11.9 ± 5.8	80.2 ± 5.9	0.7 ± 0.2	2.7 ± 0.8	N/A	0.6 ± 0

n^b	% Donor	Percentage in Donor (H2K^d+) Lymphoid Gate^c
n^b	% Donor			αβ-TCR	CD8	CD4	B220	DX5	Mac-1	Gr-1	CD11c
A^d 11	99.7 ± 0.5	20.0 ± 5.5	2.5 ± 0.9	17.6 ± 5.7	73.7 ± 5.2	6.3 ± 5.0	2.2 ± 0.5	1.0 ± 0.3	1.1 ± 0.1
B^e 10	15.6 ± 8.9	13.9 ± 6.2	1.8 ± 1.1	11.9 ± 5.8	80.2 ± 5.9	0.7 ± 0.2	2.7 ± 0.8	N/A	0.6 ± 0

Multilineage typing was performed in mice between 2 and 3 mo after second BMT.

Mice were conditioned with anti-CD154 alone or combined with anti-αβ-TCR at the primary BMT.

Mean ± SD percentage of donor cells in donor lymphoid gate.

A, Myeloablative conditioning at secondary BMT.

B, Nonmyeloablative conditioning at secondary BMT.